A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
Study Identifier
M25-491
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Recruitment Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18 - 60 Years
Protocol Summary
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
Study Locations
Location
Status
Location
CenExel ACT- Anaheim Clinical Trials /ID# 278431
Anaheim, California, United States, 92801
Status
Not applicable
Location
Acpru /Id# 273354
Grayslake, Illinois, United States, 60030
Status
Not applicable